Bali BioSciences is led by Zeil Rosenberg, MD, MPH, a vaccine, clinical trials, medical device, and precision medicine expert, who has led multi-disciplinary global teams to develop digital health platforms, novel vaccine delivery technologies, and immunotherapy products.
Dr. Rosenberg is currently Medical Director of AES, the world's largest clinical trials patient access network (comprised of Optimal Vaccine Centers of Excellence, Synexus and Acurian). He is Co-Founder and Clinical Advisor at Filament Biosolutions, a biopharmaceutical company developing oncology supportive care therapeutics for oral mucositis and peripheral neuropathy. Previous to this, he was Vice President, Medical Affairs at Admera Health, an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, and direct-to-consumer genomic digital health products. Additionally, he was Worldwide Business Leader and Medical Director, Immunization at Becton Dickinson & Co for nearly 10 years.
Dr. Rosenberg received his BA in Economics (awarded with Honors and Distinction) at Stanford, earned his MD at UCSF, completed his post-graduate medical training in Medicine and Preventive Medicine at Mt. Sinai and Cornell, respectively, and received his MPH in Epidemiology at Columbia. He was selected to serve as AAAS Science, Engineering, and Diplomacy Fellow at the US Agency for International Development. Dr. Rosenberg is a Fellow of the American College of Preventive Medicine, Specialty Fellow of the American Academy of Pediatrics, and Fellow of the New York Academy of Medicine. Dr. Rosenberg was an adjunct faculty member at Columbia's Mailman School of Public Health (1982 - 2017) where he advised start-up companies with high social impact potential.